UCB SA (UCBJY)
| Market Cap | 47.97B +12.0% |
| Revenue (ttm) | 9.74B +24.5% |
| Net Income | 2.51B +64.7% |
| EPS | 12.93 +64.9% |
| Shares Out | n/a |
| PE Ratio | 19.14 |
| Forward PE | 17.04 |
| Dividend | 0.53 (0.42%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 1,344 |
| Open | 127.22 |
| Previous Close | 126.00 |
| Day's Range | 127.22 - 127.78 |
| 52-Week Range | 111.72 - 168.76 |
| Beta | 0.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial numbers in EUR Financial StatementsNews
United Community Banks (UCB) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does United Community Banks (UCB) have what it takes? Let's find out.
UCB SA Earnings Call Transcript: H1 2026
First-half 2026 saw net sales rise 23% to EUR 4.1 billion, driven by five growth products now over half of revenue. Upgraded guidance reflects strong BIMZELX momentum, new peak sales target above EUR 7 billion, and robust pipeline expansion through acquisitions and clinical advances.
UCB SA Earnings release: H1 2026
UCB SA released its H1 2026 earnings on July 30, 2026, summarizing the period's financial results.
UCB SA Quarterly report: H1 2026
UCB SA has published its H1 2026 quarterly earnings report on July 30, 2026.
UCB SA Slides: H1 2026
UCB SA has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.
UCB shares fall despite guidance upgrade as investors question earnings quality
Belgian biopharmaceutical group UCB raised its 2026 earnings guidance on Thursday, but its shares fell more than 8% as investors focused on weaker-than-expected sales of flagship drug Bimzelx and qu...
UCB Maintained by DA Davidson -- Price Target Stays at $40
UCB Maintained by DA Davidson -- Price Target Stays at $40
UCB (UCB) Q2 2026 Earnings Call Transcript
Net interest margin expanded for sixth straight quarter as loan growth accelerated.
United Community Banks Reports Weak Q2 2026 as EPS Misses by 13.4%
Earnings Miss. United Community Banks, Inc. (UCB) reported Q2 2026 operating earnings of $0.71 per share, falling short of the $0.82 consensus estimate by 1... The post United Community Banks Reports ...
United Community Banks (UCB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for United Community Banks (UCB) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metr...
United Community Banks Inc. Bottom Line Advances In Q2
(RTTNews) - United Community Banks Inc. (UCB) revealed a profit for its second quarter that Increased, from last year
United Community Banks (UCB) Q2 2026 Preview: EPS Est. $0.82, Reports July 21
Wall Street expects United Community Banks to report earnings of $0.82 per share on revenue of $280.3 million when the regional bank releases its Q2 2026 res... The post United Community Banks (UCB) Q...
UCB SA Transcript: Investor update
BE BOLD demonstrated bimekizumab's statistically significant superiority over risankizumab in joint outcomes for psoriatic arthritis, with sustained efficacy and a safety profile consistent with prior studies. The results are expected to influence clinical guidelines, prescribing practices, and payer dynamics, supporting bimekizumab's positioning as a first-line therapy.
UCB SA Slides: Investor update
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Annual report: H2 2025
UCB SA has published its H2 2025 annual report on February 26, 2026.
UCB SA Slides: H2 2025
UCB SA has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
UCB SA Transcript: 44th Annual J.P. Morgan Healthcare Conference
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.
UCB SA Slides: 44th Annual J.P. Morgan Healthcare Conference
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
Approved indication: KYGEVVI® (doxecitine and doxribtimine) powder for oral solution (2g/2g) is approved for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with...